Soleno Therapeutics (SLNO) EBITDA Margin (2015 - 2026)

Soleno Therapeutics (SLNO) posted quarterly EBITDA Margin of 33.06% for Q1 2026, down 23.37% quarter-over-quarter from 43.15% in Q4 2025.

Soleno Therapeutics (SLNO) EBITDA Margin (2015 - 2026) Analysis & Trends

Soleno Therapeutics (SLNO) has reported EBITDA Margin for 5 consecutive years, with 33.06% the latest figure, recorded in Q1 2026.

In Q1 2026, EBITDA Margin changed N/A year-over-year to 33.06%; the TTM figure through Mar 2026 stood at 30.33% (changed N/A YoY), while the FY2025 annual figure was 4.94%, changed N/A from the prior year.
EBITDA Margin slipped to 33.06% in Q1 2026 per SLNO's latest filing, from 43.15% in the prior quarter.
Across five years, EBITDA Margin topped out at 43.15% in Q4 2025 and bottomed at 19.98% in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	30.15%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	31.68%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	19.06%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-77,569,866.34%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	19.75%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	17.93%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-0.36%
10	Soleno Therapeutics	2.74 Bn	2.49 Bn	93.41 Mn	33.06%

Download Data